Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
Atrasentan, marketed in the United States as Vanrafia, is a selective endothelin-A receptor antagonist that has added another option to the rapidly evolving treatment landscape for primary IgA nephropathy. The central question is not simply whether atrasentan lowers proteinuria. It is whether the likely incremental kidney benefit is large and durable enough to justify an expensive, monitoring-intensive therapy in a carefully selected patient.
What is atrasentan approved to do?
The U.S. Food and Drug Administration approved Vanrafia in 2025 to reduce proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression, generally described in the prescribing information as a urine protein-to-creatinine ratio of at least 1.5 g/g. The recommended dose is 0.75 mg once daily.[1]
The approval was granted through the accelerated-approval pathway and was based on proteinuria reduction. The current label states that it had not been established whether Vanrafia slows kidney-function decline in IgA nephropathy and that continued approval may depend on confirmation of clinical benefit in a confirmatory trial.[1] Final ALIGN results published in 2026 provide encouraging kidney-function data, but they do not eliminate the need to understand this regulatory distinction.
Which patient profile most closely matches the evidence?
The best-supported candidate is an adult with biopsy-confirmed primary IgA nephropathy, persistent substantial proteinuria despite optimized supportive care, and an eGFR of at least 30 mL/min/1.73 m². The ALIGN trial enrolled patients with urinary protein of at least 1.0 g/day despite renin–angiotensin-system inhibition; participants generally had a stable, maximally tolerated ACE inhibitor or ARB unless they were unable to tolerate it.[2] [3]
| Patient feature | Why it matters |
|---|---|
| Persistent proteinuria | Proteinuria is the main modifiable risk marker targeted by atrasentan and the basis of the accelerated approval. |
| eGFR ≥30 mL/min/1.73 m² | This reflects the principal ALIGN eligibility threshold; evidence is less direct below this level. |
| Optimized background therapy | Atrasentan should be considered an add-on strategy, not a replacement for blood-pressure control, sodium reduction, tolerated RAS blockade, or an appropriate SGLT2 inhibitor. |
| High progression risk | The potential absolute benefit is more persuasive when the untreated risk of kidney-function loss is substantial. |
| Low risk of fluid complications | Endothelin-receptor antagonism can cause fluid retention, and Vanrafia was not evaluated in IgAN patients with heart failure. |
| Reproductive and hepatic safety feasible | Pregnancy is contraindicated; pregnancy testing, contraception counseling, liver assessment, and interaction review are essential. |
This profile argues against routine use for every patient with IgA nephropathy. A patient with low residual proteinuria, stable low-risk disease, advanced kidney failure outside the studied population, uncontrolled congestion, severe hepatic impairment, or an important interacting medication may have a less favorable risk–benefit balance.
What did the final ALIGN trial show?
ALIGN was a randomized, double-blind, placebo-controlled phase 3 trial. It included 404 participants: 340 in the main stratum and 64 in an exploratory stratum receiving a stable SGLT2 inhibitor. Participants received atrasentan 0.75 mg daily or placebo for 132 weeks, followed by a short off-treatment assessment.[2]
In the main stratum, the mean eGFR change by week 136 was −7.5 mL/min/1.73 m² with atrasentan and −9.9 mL/min/1.73 m² with placebo. The between-group difference was 2.4 mL/min/1.73 m², with a 95% confidence interval from −0.1 to 4.8 and p=0.057. The difference in total eGFR slope was 1.4 mL/min/1.73 m² per year, and the end-of-treatment difference was 2.6 mL/min/1.73 m².[2]
These findings are clinically encouraging because they are directionally consistent with kidney-function preservation. However, the primary week-136 confidence interval crossed zero. The appropriate interpretation is therefore promising evidence of a modest slowing signal, not definitive proof that atrasentan prevents kidney failure. The exploratory SGLT2-inhibitor stratum showed a larger week-136 difference, but its smaller size means that it should not be interpreted as conclusive evidence of synergy.[2]
The trial reported no new safety signals, and treatment-emergent adverse events were broadly balanced. Nevertheless, the study was funded by Novartis, and several investigators reported relationships with the sponsor. This does not invalidate the results, but it supports careful interpretation of effect size and independent confirmation over time.[2]
Safety issues that influence patient selection
The most important safety issue is fluid retention. In the label’s ALIGN safety population, peripheral edema occurred in 10% of atrasentan-treated patients compared with 7% receiving placebo; anemia occurred in 6% versus 1%, and clinically relevant transaminase elevations occurred in 2% versus 1%.[1] In the final publication, fluid-retention adverse events in the main stratum occurred in 14% with atrasentan and 12% with placebo.[2]
Vanrafia carries a boxed warning for embryo–fetal toxicity. Pregnancy must be excluded before treatment, effective contraception is required during treatment and for two weeks after discontinuation, and treatment should be stopped if pregnancy occurs. The label also warns about hepatotoxicity and decreased sperm counts. Baseline liver-enzyme testing, clinically appropriate follow-up, review of hemoglobin and volume status, and medication-interaction screening are part of responsible use.[1]
Clinical impact versus cost
The manufacturer’s U.S. patient-support site lists a 30-day price of $14,291.09. Annualized without discounts, rebates, insurance, assistance, or cost-sharing, that is approximately $171,493.08 per year.[4] This is a list-price calculation, not a typical patient out-of-pocket cost. Actual exposure depends on insurance type, formulary placement, prior authorization, deductibles, coinsurance, and eligibility for assistance.
| Value question | Current assessment |
|---|---|
| Is there a biological and antiproteinuric rationale? | Yes. Atrasentan is a selective endothelin-A antagonist and reduces proteinuria in the studied high-risk population. |
| Is kidney-function benefit established? | Not conclusively under the original accelerated-approval standard. Final ALIGN data are encouraging but the principal week-136 estimate was not statistically definitive. |
| Does the price appear modest relative to evidence? | No. A list price above $170,000 annually places a high value threshold on the incremental benefit. |
| Where is the economic case strongest? | In patients with high baseline progression risk, substantial residual proteinuria, adequate eGFR, few safety barriers, and a credible possibility of preventing or substantially delaying kidney failure. |
| Where is the economic case weakest? | In low-risk disease, minimal residual proteinuria, significant congestion risk, limited life expectancy, or when the patient’s actual coverage leaves a large unaffordable cost. |
From a health-system perspective, the price is difficult to justify on short-term proteinuria reduction alone. The value proposition improves if the eGFR-slope signal is confirmed, if benefit is concentrated in patients at very high risk, and if the therapy prevents costly kidney-failure outcomes. A key unanswered question is how many months or years of dialysis, transplantation, or major morbidity must be avoided for atrasentan to become cost-effective under a particular payer’s threshold.
For an individual patient, the relevant figure is not the list price but the verified annual cost under that patient’s insurance. Assistance programs may lower access barriers, but eligibility and coverage can change. Affordability should be assessed before treatment rather than assumed from promotional statements about support.
How should clinicians frame a treatment discussion?
A practical discussion should begin by confirming persistent proteinuria and estimating progression risk from the eGFR trajectory, proteinuria, blood pressure, biopsy findings, and validated IgA nephropathy risk tools where appropriate. Supportive treatment should be optimized first. The clinician and patient should then weigh the anticipated incremental benefit against fluid-retention risk, reproductive requirements, monitoring, drug interactions, insurance restrictions, and actual out-of-pocket cost.
The most accurate shared-decision statement is not that atrasentan “prevents kidney failure.” It is that atrasentan is an approved add-on therapy for proteinuria reduction in a high-risk adult population, with final ALIGN data suggesting a modest slowing of eGFR decline over 2.5 years, while the magnitude and durability of kidney-failure prevention remain less certain than the price might imply.
Key clinical takeaways
- Atrasentan is best considered for an adult with primary IgA nephropathy, persistent substantial proteinuria, eGFR at least 30 mL/min/1.73 m², and residual risk despite optimized supportive care.
- The strongest established treatment effect is proteinuria reduction; final ALIGN results suggest, but do not definitively prove, slower eGFR decline.
- Fluid retention, edema, anemia, hepatic safety, pregnancy prevention, fertility counseling, and drug interactions materially influence patient selection.
- The U.S. manufacturer-reported list price is $14,291.09 per 30 days, or approximately $171,493 annually before discounts and coverage effects.
- At this price, atrasentan’s value is most persuasive when treatment is targeted to patients with high untreated progression risk and a realistic chance of avoiding or delaying kidney failure.
References
- DailyMed. VANRAFIA (atrasentan) Prescribing Information.
- Heerspink HJL, et al. Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2026.
- ClinicalTrials.gov. Atrasentan in Patients With IgA Nephropathy (ALIGN), NCT04573478.
- Novartis Patient Support. VANRAFIA list-price and assistance information.